CRLCharles River Laboratories
Is the price fair?
A demanding price: priced for +16% a year vs −1% a year delivered and rich vs its sector.
Priced for ~16% a year FCF growth. The price already bakes in strong, sustained growth.
In its normal range: P/E 24.8 vs a 28.5 median over 33 quarters (−13% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 27, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CRL's price assumes
Today's price asks for 16% free cash flow growth a year; over the last three years Charles River Laboratories delivered +8.6%, so the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.3%
Free cash flow yield · Diagnostics & Research median 2.9%
- Growth the price implies
- +16%
Growth the price implies · The price pays for +16% free cash flow growth a year for a decade; the business has delivered +8.6% a year over the last three.
- Price / book
- 5.81
Price / book · today's price, trailing year to Jun 27, 2026
Details›
- Price / booktoday's price, trailing year to Jun 27, 2026
- 5.81
- EV / EBIToperating margin 2.3%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 27, 2026
- 4.73
- Free cash flow, trailing twelve months
- $371M
- Market capitalisation47.7 million shares, counted Jul 25, 2026
- $16.5B
- 3-year revenue growth
- −1.5%
- 3-year free cash flow growth
- +8.6%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Diagnostics & Research
The closest names by size in the same industry